Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300880 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Alexandra A Abu-Shmais und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Parainfluenza Virus 3, Human. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIGMS NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Human parainfluenza virus 3 (HPIV3) is a widespread pathogen causing severe and lethal respiratory illness in at-risk populations. Effective countermeasures are in various stages of development; however, licensed therapeutic and prophylactic options are not available. The fusion glycoprotein (HPIV3 F), responsible for facilitating viral entry into host cells, is a major target of neutralizing Abs that inhibit infection. Although several neutralizing Abs against a small number of HPIV3 F epitopes have been identified to date, relatively little is known about the Ab response to HPIV3 compared with other pathogens, such as influenza virus and SARS-CoV-2. In this study, we aimed to characterize a set of HPIV3-specific Abs identified in multiple individuals for genetic signatures, epitope specificity, neutralization potential, and publicness. We identified 12 potently neutralizing Abs targeting three nonoverlapping epitopes on HPIV3 F. Among these, six Abs identified from two different individuals used Ig heavy variable gene IGHV 5-51, with five of the six Abs targeting the same epitope. However, despite the use of the same H chain variable (VH) gene, these Abs used multiple different L chain variable genes (VL) and diverse H chain CDR 3 (CDRH3) sequences. Together, these results provide further information about the genetic and functional characteristics of HPIV3-neutralizing Abs and suggest the existence of a reproducible VH-dependent Ab response associated with VL and CDRH3 promiscuity. Understanding sites of HPIV3 F vulnerability and the genetic and molecular characteristics of Abs targeting these sites will help guide efforts for effective vaccine and therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN.
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA.
- Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA.
- Program in Chemical and Physical Biology, Vanderbilt University Medical Center; Nashville, TN.
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
ORCID-Profile: Alexandra A Abu-Shmais, Rose J Miller, Alexis K Janke, Rachael M Wolters, Clinton M Holt, Nagarajan Raju, Robert H Carnahan, James E Crowe, Jarrod J Mousa
Förderung
- NIH HHS
- NIGMS NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- NEI NIH HHS
- NCI NIH HHS
- NCRR NIH HHS
- NCATS NIH HHS
Zitieren
APA
Abu-Shmais, A. A., Miller, R. J., Janke, A. K., Wolters, R. M., Holt, C. M., Raju, N., Carnahan, R. H., Crowe, J. E., Mousa, J. J., & Georgiev, I. S. (2024). Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300880
Vancouver
Abu-Shmais AA, Miller RJ, Janke AK, Wolters RM, Holt CM, Raju N, et al. Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300880
BibTeX
@article{AbuShmais2024,
author = {Abu-Shmais, Alexandra A and Miller, Rose J and Janke, Alexis K and Wolters, Rachael M and Holt, Clinton M and Raju, Nagarajan and Carnahan, Robert H and Crowe, James E and Mousa, Jarrod J and Georgiev, Ivelin S},
title = {Potent HPIV3-neutralizing IGHV5-51 Antibodies Identified from Multiple Individuals Show L Chain and CDRH3 Promiscuity},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300880}
}
EUVIMED